L'information financière que vous ne trouvez
nulle part ailleurs !

Actualité

Nous sélectionnons chaque jour les news que nous estimons importantes pour pouvoir suivre les points suivants :

Date de publication: 30 mars 2011
Auteur: YB
Noter cette article :
SEC.jpg

La Securities and Exchange Commission a publié un communiqué dans lequel elle dénonce un chimiste de la FDA pour information privilégiée.

Lire le communiqué

Résumé officiel :

The Securities and Exchange Commission today charged a U.S. Food and Drug Administration (FDA) chemist with insider trading on confidential information about upcoming announcements of FDA drug approval decisions, generating more than $3.6 million in illicit profits and avoided losses.

The SEC alleges that Cheng Yi Liang illegally traded in advance of at least 27 public announcements about FDA drug approval decisions involving 19 publicly traded companies. Some announcements concerned the FDA's approval of new drugs while others concerned negative FDA decisions. In each instance, he traded in the same direction as the announcement. Liang went to great lengths to conceal his insider trading. He traded in seven brokerage accounts, none of which were in his name. One belonged to his 84-year-old mother who lives in China.

Mots-clés :
Chimie